Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer

L Yu, J Wei, P Liu - Seminars in cancer biology, 2022 - Elsevier
Cancer is the second leading cause of human death globally. PI3K/Akt/mTOR signaling is
one of the most frequently dysregulated signaling pathways observed in cancer patients that …

Breast cancer treatments: updates and new challenges

A Burguin, C Diorio, F Durocher - Journal of personalized medicine, 2021 - mdpi.com
Breast cancer (BC) is the most frequent cancer diagnosed in women worldwide. This
heterogeneous disease can be classified into four molecular subtypes (luminal A, luminal B …

Targeting PI3K in cancer: mechanisms and advances in clinical trials

J Yang, J Nie, X Ma, Y Wei, Y Peng, X Wei - Molecular cancer, 2019 - Springer
Abstract Phosphatidylinositol-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR)
signaling is one of the most important intracellular pathways, which can be considered as a …

Activation of PI3K/AKT/mTOR pathway causes drug resistance in breast cancer

C Dong, J Wu, Y Chen, J Nie, C Chen - Frontiers in pharmacology, 2021 - frontiersin.org
Although chemotherapy, targeted therapy and endocrine therapy decrease rate of disease
recurrence in most breast cancer patients, many patients exhibit acquired resistance …

Targeting the PI3K pathway in cancer: are we making headway?

F Janku, TA Yap, F Meric-Bernstam - Nature reviews Clinical oncology, 2018 - nature.com
Abstract The PI3K–AKT–mTOR pathway is one of the most frequently dysregulated
pathways in cancer and, consequently, more than 40 compounds that target key …

PI3K inhibitors in cancer: clinical implications and adverse effects

R Mishra, H Patel, S Alanazi, MK Kilroy… - International journal of …, 2021 - mdpi.com
The phospatidylinositol-3 kinase (PI3K) pathway is a crucial intracellular signaling pathway
which is mutated or amplified in a wide variety of cancers including breast, gastric, ovarian …

Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials

Z Niu, R Jin, Y Zhang, H Li - Signal Transduction and Targeted Therapy, 2022 - nature.com
Lung cancer is the leading cause of cancer-related death across the world. Unlike lung
adenocarcinoma, patients with lung squamous cell carcinoma (LSCC) have not benefitted …

[HTML][HTML] De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of …

G Curigliano, HJ Burstein, EP Winer, M Gnant… - Annals of …, 2017 - Elsevier
ABSTRACT The 15th St. Gallen International Breast Cancer Conference 2017 in Vienna,
Austria reviewed substantial new evidence on loco-regional and systemic therapies for early …

A review of nanotechnology-based approaches for breast cancer and triple-negative breast cancer

V Jain, H Kumar, HV Anod, P Chand, NV Gupta… - Journal of Controlled …, 2020 - Elsevier
Breast cancer (BC) is one of the most prevalent cancers in women. Triple-negative breast
cancer (TNBC) in which the three major receptors ie estrogen receptor (ER), progesterone …

[HTML][HTML] Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment

HK Patel, T Bihani - Pharmacology & therapeutics, 2018 - Elsevier
Breast cancer is the most frequently diagnosed cancer in women, with estrogen receptor
positive (ER+) breast cancer making up approximately 75% of all breast cancers diagnosed …